drugset
Drugs / QL2107
last change 3 days ago re-read 2 minutes ago

QL2107

Developed for
neoplasm · non-small cell lung carcinoma · bile duct carcinoma · endometrial cancer · gastric adenocarcinoma · gastric cancer · gastroesophageal junction adenocarcinoma · neoplastic disease or syndrome
+1 more · ovarian cancer
Investigated by
Qilu Pharmaceutical Co., Ltd.

Trials 9 · a red edge is where a trial was stopped

today NCT07453394 · Ph 1/2 NCT07256782 · Ph 1/2 NCT07151872 · Ph 2 NCT07162883 · Ph 3 NCT06949761 · Ph 1/2 NCT06942767 · Ph 2 NCT06911827 · Ph 1/2 NCT06754644 · Ph 3 NCT06173011 · Ph 1
20242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT06173011 Dec 2023 → Jul 2024 neoplasm Qilu Pharmaceutical Co., Ltd. Unknown No outcome recorded
Phase 1/24 trials
Phase 1/2 NCT07453394 Apr 2026 → Apr 2027 expected endometrial cancer, gastric cancer, non-small cell lung carcinoma, ovarian cancer Qilu Pharmaceutical Co., Ltd. Not yet recruiting No outcome recorded
Phase 1/2 NCT07256782 Oct 2025 → Oct 2026 expected neoplastic disease or syndrome Qilu Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 1/2 NCT06949761 Jun 2025 → Sep 2026 expected neoplasm Qilu Pharmaceutical Co., Ltd. Not yet recruiting No outcome recorded
Phase 1/2 NCT06911827 May 2025 → Dec 2027 expected neoplasm Qilu Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 22 trials
Phase 2 NCT07151872 Sep 2025 → Oct 2026 expected bile duct carcinoma Qilu Pharmaceutical Co., Ltd. Not yet recruiting No outcome recorded
Phase 2 NCT06942767 Jun 2025 → Dec 2026 expected gastric adenocarcinoma, gastroesophageal junction adenocarcinoma Qilu Pharmaceutical Co., Ltd. Not yet recruiting No outcome recorded
Phase 32 trials
Phase 3 NCT07162883 Sep 2025 → Dec 2026 expected non-small cell lung carcinoma Qilu Pharmaceutical Co., Ltd. Not yet recruiting No outcome recorded
Phase 3 NCT06754644 Jan 2025 → Dec 2026 expected non-small cell lung carcinoma Qilu Pharmaceutical Co., Ltd. Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as QL2107 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06911827 ↗
8

NCT07256782 ↗

NCT06949761 ↗

NCT07151872 ↗

NCT06173011 ↗

NCT07453394 ↗

NCT06754644 ↗

NCT06942767 ↗

NCT07162883 ↗
Route Intravenous “intravenous infusion” NCT06173011 ↗